Vycor Medical Reports 9% Revenue Growth and Continued Development in Medical Device and Vision Therapy Sectors
TL;DR
Vycor Medical's revenues increased by 10% in 2024, with 17% growth in US hospital sales, offering a competitive advantage in the medical device industry.
Vycor Medical's ViewSite™ Brain Access System (VBAS) has been validated through 43 peer-reviewed studies, demonstrating its effectiveness in improving surgical outcomes.
Vycor Medical's products like VBAS and NovaVision are changing lives by providing innovative surgical and therapeutic solutions to help patients recover from neurological brain damage.
Vycor Medical engaged Maxim Group LLC to accelerate growth and explore strategic partnerships, positioning itself for potential uplisting to a US exchange, offering exciting opportunities for stakeholders.
Found this article helpful?
Share it with your network and spread the knowledge!
Vycor Medical reported a 9% revenue increase for the year ended December 31, 2024, with its Vycor Medical division driving growth through expanded hospital penetration and sales. The company's total revenue reached $1,589,324, up from $1,460,604 in 2023, primarily driven by a 17% increase in sales to US hospitals.
The ViewSite Brain Access System (VBAS) demonstrated significant clinical validation through eight new peer-reviewed studies, including a comprehensive 106-patient study evaluating its effectiveness in glioma removal. These studies highlighted the system's potential to reduce tissue damage, improve surgical visualization, and potentially enhance patient outcomes.
Despite modest financial performance, Vycor Medical remains committed to product development and strategic growth. The company has engaged Maxim Group LLC to explore potential strategic acquisitions, partnerships, and potential uplisting to a US exchange, signaling an aggressive approach to expanding market presence.
The NovaVision division, focusing on vision rehabilitation therapies, continues to develop its therapeutic programs while generating relatively modest revenues. The company recognizes the need for further development to fully realize the market potential of its vision restoration technologies.
Financial challenges persist, with the company reporting a net loss of $431,570 for the year. However, management remains optimistic about future growth potential, particularly in neurosurgical and vision rehabilitation markets.
Curated from NewMediaWire
